1. Nat. Rev. Cardiol. doi:10.1038/nrcardio.2015.113
Figure 7 Pharmacodynamics profile of switching therapy from ticagrelor to prasugrel: results from the SWAP‑2 study
Figure 7| Pharmacodynamics profile of switching therapy from ticagrelor to prasugrel: results from the SWAP-2 study.82 Time course of platelet inhibition as measured with P2Y12 reaction units in patients with stable coronary artery disease. The results at time 0 (pre-run-in baseline) are the baseline values obtained when patients were receiving aspirin, before the ticagrelor LD was administered. The second baseline values (pre-randomization baseline) were obtained immediately before the first dose of randomized drug was administered, after the run-in phase was completed. 12 h after the last ticagrelor MD was given, patients were randomly assigned to one of three regimens. Data are presented as mean ± SD. Abbreviations: LD, loading dose; MD, maintenance dose. Modified from Angiolillo, D. J. et al. Pharmacodynamic evaluation of switching from ticagrelor to prasugrel in patients with stable coronary artery disease: results of the SWAP-2 study (Switching Anti Platelet-2). J. Am. Coll. Cardiol. 63 (15), 1500–1509 © (2014), with permission from Elsevier and the American College of Cardiology.
Modified from Angiolillo, D. J. et al. Pharmacodynamic evaluation of switching from ticagrelor to prasugrel in patients with stable coronary artery disease: results of the SWAP‑2 study (Switching Anti Platelet‑2). J. Am. Coll. Cardiol. 63 (15), 1500–1509 © (2014), with permission from Elsevier and the American College of Cardiology
Rollini, F. et al. (2015) Switching P2Y12-receptor inhibitors in patients with coronary artery disease
Nat. Rev. Cardiol. doi: /nrcardio